133 related articles for article (PubMed ID: 2545342)
1. Significant increase in the antibody to Gal alpha 1-3Gal structure in sera of patients with hepatocellular carcinoma after transcatheter arterial embolization.
Kashiwagi M; Ikeda Y; Iwamori M; Toda G; Nagai Y
Cancer Res; 1989 Aug; 49(16):4396-401. PubMed ID: 2545342
[TBL] [Abstract][Full Text] [Related]
2. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients.
Zhou SF; Xie XX; Bin YH; Lan L; Chen F; Luo GR
Clin Chim Acta; 2006 Apr; 366(1-2):274-80. PubMed ID: 16356486
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy.
Kaneko A; Hayashi N; Tanaka Y; Ito T; Kasahara A; Kubo M; Mukuda T; Fusamoto H; Kamada T
Am J Gastroenterol; 1992 Aug; 87(8):1014-7. PubMed ID: 1322635
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
5. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.
Hann HW; Lee J; Bussard A; Liu C; Jin YR; Guha K; Clayton MM; Ardlie K; Pellini MJ; Feitelson MA
Cancer Res; 2004 Oct; 64(20):7329-35. PubMed ID: 15492253
[TBL] [Abstract][Full Text] [Related]
6. Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury.
Moody DE; Loury DN; Hammock BD; Ruebner BH; Cullen JM; Hillman JH; Hillman DW; Rao MS; London WT; Hann HW
Cancer Epidemiol Biomarkers Prev; 1992; 1(5):395-403. PubMed ID: 1339049
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
Chen DS
Princess Takamatsu Symp; 1995; 25():27-32. PubMed ID: 8875606
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
9. [Changes in ketone body ratio and levels of pyruvate and lactate in arterial blood of patients with hepatocellular carcinoma after transcatheter arterial embolization].
Mizobuchi N; Kuwao F; Takeda I; Takemura T; Morita S; Horimi T; Takahashi I
Rinsho Byori; 1990 Jul; 38(7):825-9. PubMed ID: 2169547
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.
Akamatsu M; Yoshida H; Obi S; Sato S; Koike Y; Fujishima T; Tateishi R; Imamura M; Hamamura K; Teratani T; Shiina S; Ishikawa T; Omata M
Liver Int; 2004 Dec; 24(6):625-9. PubMed ID: 15566514
[TBL] [Abstract][Full Text] [Related]
11. Serum hepatocyte growth factor levels in liver diseases: clinical implications.
Shiota G; Okano J; Kawasaki H; Kawamoto T; Nakamura T
Hepatology; 1995 Jan; 21(1):106-12. PubMed ID: 7806142
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Watanabe N
Autoimmunity; 2005 Sep; 38(6):445-8. PubMed ID: 16278150
[TBL] [Abstract][Full Text] [Related]
13. Detection and characterization of antibody to liver cell membrane in sera from patients with chronic active liver diseases.
Tsuji T; Araki K; Naito K; Inoue J; Nacashima H
Acta Med Okayama; 1979 Feb; 33(1):61-6. PubMed ID: 220848
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis Be antigen and antibody in chronic liver diseases and hepatocellular carcinoma.
Chen DS; Sung JL; Lai MY
Hepatogastroenterology; 1981 Dec; 28(6):288-91. PubMed ID: 6284625
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.
Yamashita F; Tanaka M; Satomura S; Tanikawa K
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):627-33. PubMed ID: 8590157
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
Shimizu Y; Minemura M; Tsukishiro T; Kashii Y; Miyamoto M; Nishimori H; Higuchi K; Watanabe A
Hepatology; 1995 Aug; 22(2):525-31. PubMed ID: 7543436
[TBL] [Abstract][Full Text] [Related]
17. [Transcatheter arterial embolization for advanced hepatocellular carcinoma--indications and limitations].
Nakamura H; Kawata S; Takamura M; Osuga K; Murakami T
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1509-15. PubMed ID: 11015994
[TBL] [Abstract][Full Text] [Related]
18. Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolization.
Yamazaki H; Nishimoto N; Oi H; Matsushita M; Ogata A; Shima Y; Inoue T; Tang JT; Yoshizaki K; Kishimoto T
Cytokine; 1995 Feb; 7(2):191-5. PubMed ID: 7780039
[TBL] [Abstract][Full Text] [Related]
19. Definition of tumor-associated antigens in hepatocellular carcinoma.
Stenner-Liewen F; Luo G; Sahin U; Tureci O; Koslovski M; Kautz I; Liewen H; Pfreundschuh M
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):285-90. PubMed ID: 10750667
[TBL] [Abstract][Full Text] [Related]
20. First establishment of a human monoclonal antibody directed to sulfated glycosphingolipids SM4s-Gal and SM4g, from a patient with lung cancer.
Miyake M; Taki T; Kannagi R; Hitomi S
Cancer Res; 1992 Apr; 52(8):2292-7. PubMed ID: 1313742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
